Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 795

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 795
---
 of $ 10.00per share in a concurrent private placement. The Common Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The Company has also agreed that from the date of the Purchase Agreement until one year after the closing date of the offering, the Company shall not enter into an agreement to effect any issuance by the Company or any of the Company’s subsidiaries of Company Common Shares or common share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross proceeds to the Company of $ 1,750,000and expenses of approximately $ 321,000. Warrants On October 9, 2024, the Company and certain existing warrant holders entered into warrant amendment agreements, or collectively, the Amendment, to amend those warrants issued by Company to such holders, collectively, to purchase up to 105,843Common Shares issued to such holders, or the Existing Warrants. The Amendment makes certain Annex F-23 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

adjustment to the definition of a “Fundamental Transaction” in Section 3(e) of the Existing Warrants. In exchange for the Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.80and issued to the holders Pre -FundedWarrants to purchase up to 136,648Common Shares, or the Pre -FundedWarrants. Each Pre -FundedWarrant is exercisable for one Common Share at an exercise price of CHF 0.80per share. The Pre -FundedWarrants are immediately exercisable and may be exercised at any time until all of the Pre -FundedWarrants are exercised in full. On September 16, 2024, the Company and an institutional investor entered into a warrant amendment agreement to amend warrants to purchase up to 172,836common shares, par value CHF 0.80. The amendment adjusted the definition of a “Fundamental Transaction” and the exercise price to CHF 0.80. Following an increase in authorized common shares, the Company will issue pre -fundedwarrants to purchase up to 191,431common shares for aggregate proceeds of $ 153,144. The Company has reflected a deemed dividend totaling $ 2,076,180for the incremental value from the modification of the warrants’ exercise price and the fair value of the warrants